With respect to the implementation of Nrf2 targeted therapies, it will be important to analyze in which CKD stages or kidney diseases Nrf2-activating or Nrf2-modifying therapies can effectively support the endogenous Nrf2 activity and/or Nrf2 targets. The gene discussed is NFE2L2; the disease is kidney disorder.